Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ThermoGenesis Holdings, Inc. THMO

Healthcare  —  Medical Devices
0.00 0.00 NaN as of 24 Sep
Market cap
$1.1M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

ThermoGenesis Holdings, Inc. (THMO) Business Profile

Updated before January 2025

Company Overview

ThermoGenesis Holdings, Inc. (NASDAQ: THMO) is a leading company in the field of cell and gene therapy technologies. Founded in 1986 and headquartered in Rancho Cordova, California, the company has been at the forefront of developing innovative solutions for the biopharmaceutical and healthcare industries. Over the years, ThermoGenesis has evolved from a small startup to a publicly traded company, with a strong focus on advancing regenerative medicine and cell-based therapies. The company is led by a team of experienced professionals, including its CEO, Chris Xu, Ph.D., who has been instrumental in driving the company’s strategic vision and growth.

Core Business Segments

ThermoGenesis operates through several core business segments, each catering to specific needs within the cell and gene therapy market. These segments include:

1. Automated Cell Processing Systems

ThermoGenesis is renowned for its automated cell processing systems, which are designed to streamline and enhance the efficiency of cell therapy manufacturing. Key products in this category include:

  • X-Series® Products: These systems are used for isolating and processing stem cells from various sources, such as bone marrow and cord blood.
  • CAR-TXpress™ Platform: A cutting-edge solution for the manufacturing of CAR-T cell therapies, which are used in cancer treatment.

2. BioBanking Solutions

The company provides advanced biobanking solutions for the storage and preservation of cellular materials. These solutions are critical for research and therapeutic applications. Products include:

  • AXP® Automated Cell Separation System: Designed for the efficient processing of cord blood.
  • BioArchive® System: A state-of-the-art cryopreservation system for long-term storage of cellular products.

3. Contract Development and Manufacturing Services (CDMO)

ThermoGenesis offers contract development and manufacturing services to support the production of cell and gene therapies. These services include:

  • Process development and optimization.
  • GMP-compliant manufacturing.
  • Quality control and regulatory support.

4. Clinical and Research Tools

The company also provides tools and technologies for clinical and research applications, enabling scientists and clinicians to advance their work in regenerative medicine.

Business Model

ThermoGenesis operates on a business model that integrates product innovation, service delivery, and strategic partnerships. The company generates revenue through the sale of its proprietary products, licensing agreements, and contract manufacturing services. By focusing on automation and scalability, ThermoGenesis aims to reduce the cost and complexity of cell therapy manufacturing, making these treatments more accessible to patients worldwide.

Strategic Direction

ThermoGenesis is committed to driving innovation in the cell and gene therapy space. The company’s strategic priorities include:

  • Expansion of CDMO Services: Increasing capacity and capabilities to meet the growing demand for cell and gene therapy manufacturing.
  • Sustainability Goals: Implementing eco-friendly practices in product development and manufacturing processes.
  • New Product Development: Investing in research and development to introduce next-generation technologies for regenerative medicine.
  • Global Expansion: Exploring opportunities to expand its presence in international markets.

Competitive Landscape

ThermoGenesis operates in a highly competitive market, with key competitors including:

  • Fresenius Kabi: A global leader in biopharmaceutical manufacturing and cell therapy solutions.
  • Miltenyi Biotec: Known for its advanced cell separation and analysis technologies.
  • Lonza Group: A major player in the contract development and manufacturing space for cell and gene therapies.
  • BioLife Solutions: Specializes in biopreservation media and automated thawing devices.

Despite the competition, ThermoGenesis differentiates itself through its focus on automation, scalability, and cost-effectiveness.

Risk Factors

Like any company, ThermoGenesis faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Market Dependence: Reliance on the cell and gene therapy market, which is still in its early stages of growth.
  • Regulatory Challenges: Navigating complex regulatory requirements for product approval and manufacturing.
  • Supply Chain Disruptions: Potential delays or shortages in the supply of raw materials and components.
  • Technological Obsolescence: The risk of competitors developing more advanced technologies.

Recent Developments

ThermoGenesis has made significant strides in recent years, including:

  • Launch of New Products: Introduction of advanced cell processing systems and biobanking solutions.
  • Strategic Partnerships: Collaborations with leading biopharmaceutical companies to expand its service offerings.
  • COVID-19 Impact: Adjustments to operations and supply chains to address challenges posed by the global pandemic.

Investment Considerations

Investors considering ThermoGenesis should weigh the following factors:

Strengths:

  • Strong focus on innovation and automation.
  • Established presence in the growing cell and gene therapy market.
  • Diversified revenue streams from products and services.

Risks:

  • High dependence on a niche market.
  • Regulatory and competitive pressures.
  • Potential financial volatility due to market uncertainties.

Conclusion

ThermoGenesis Holdings, Inc. is a pioneering company in the cell and gene therapy industry, with a strong track record of innovation and a clear strategic vision. While the company faces challenges, its focus on automation, scalability, and cost-effectiveness positions it well for future growth. As the demand for regenerative medicine continues to rise, ThermoGenesis is poised to play a key role in shaping the future of healthcare.